Biomarkers In Inflammatory Disease Research Articles

Early Upregulation of Peripheral Benzodiazepine Receptor Expression by Radiation-Induced Damage to Mouse Lung In Vivo

Peripheral benzodiazepine receptor (PBR) is long considered to be a useful noninvasive imaging biomarker for inflammatory diseases. For instance, 11C-(R)-PK11195, a radio-labeled PBR specific binding ligand, has been used to image brain injury in both preclinical and clinical studies. The purpose of this study is to determine if PBR expression is upregulated in irradiated mouse lung parenchyma as it relates to the early detection of radiation-induced pulmonary injury.

Novel immuno-spin trapping-based assay for the analysis of myeloperoxidase (100.13)

Abstract Myeloperoxidase (MPO) is an important biomarker of inflammatory diseases. The analyses of MPO in biological samples are based on detection of its peroxidase activity, chloramine formation, and MPO-capture immunoassays. We have developed an immuno-spin trapping (IST)-based approach to determine MPO in biological samples. In this approach, MPO/H2O2/Cl system produces hypochlorous acid (HOCl);HOCl reacts with proteins forming chloramines;chloramines decay forming protein radicals,protein radicals are trapped by the nitrone spin trap 5,5-dimethyl-1-pyrroline N-oxide (DMPO) forming DMPO-protein nitrone adducts, andnitrone adducts are determined using a chemiluminescent direct ELISA with the anti-DMPO antiserum. We used this assay to quantify MPO in plasma, bronchoalveolar fluid and lung parenchyma of rats exposed to lipopolysaccharide, and compared its sensitivity with a capture-based commercial ELISA kit. Hemoglobin does not interfere and the assay can be used in animal and human samples. The assay has three levels of amplification: enzymatic formation of HOCl;many DMPO molecules bound per single protein molecule;a sensitive developing system. The IST-based assay for quantification of MPO will enhance the power of this biomarker for early detection of environmental- and metabolic-induced inflammatory disorders in both experimental and clinical settings. NIH#1K99 ES015414-01